Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
about
The reversal of antineoplastic drug resistance in cancer cells by β-elemeneMultiple Drug Transport Pathways through Human P-Glycoprotein.Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma CellsDisrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cellsNovel delivery approaches for cancer therapeutics.Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.Multidrug resistance in oncology: diagnostic and therapeutic approaches.Overcoming multiple drug resistance mechanisms in medulloblastoma.Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo.ABC transporters: unvalidated therapeutic targets in cancer and the CNSMDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cellsGenetics of multidrug resistance.Clinical relevance of P-glycoprotein in drug therapy.Reversal of MDR by verapamil analogues.Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies.Phase I and pharmacokinetic study of D-verapamil and doxorubicin.High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancerVerapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoproteinMultidrug resistance (mdr) genes in human cancer.The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene.Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's diseaseAsclepiasterol, a novel C21 steroidal glycoside derived from Asclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression.The clinical relevance of multidrug resistance.Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?Pharmacogenetics of genes across the doxorubicin pathway.Investigational ABC transporter inhibitors.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?Decursin in Angelica gigas Nakai (AGN) Enhances Doxorubicin Chemosensitivity in NCI/ADR-RES Ovarian Cancer Cells via Inhibition of P-glycoprotein Expression.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.
P2860
Q26787004-5FF01E6E-77E7-4962-A817-6648886D2C71Q27301793-B6ED49DF-4736-4594-9D74-E6221C4B9F1CQ27321292-CC5EC8B4-EABF-4ABA-8F67-AC342354C6D6Q28069761-B21E212E-F83F-4397-8597-4595A71B7755Q28368394-437E03A7-7E50-4223-93D2-9559A67898C2Q30368171-009CD017-B331-4E55-8F03-CAAADDA98963Q32063216-801BD721-3746-49BD-854A-65FCDA5561F2Q33377470-4D21ABCA-4F19-4EC9-9071-98A259104344Q33650232-F1086112-C62F-4A16-8600-CCE7D9FEA921Q34500602-9587E607-055C-4A4B-9A5A-2D9BE9760BE0Q34613849-5247D512-5555-412E-90A3-E1AB52D81CD0Q34634236-C0382742-C8ED-476B-A388-4DA13E56E42BQ35056738-6F2415B8-DFC4-4724-B47D-40FE436AB87DQ35089472-528B9192-4B00-4FBB-A97D-270C5830C11CQ35267029-9C24CBC4-B10F-47E5-8D99-41B839213E47Q35587246-DD853F49-3AAA-4B3D-9700-E0480AF69926Q35620664-6F10F173-B06C-49CE-9592-C808AA9E7998Q35668684-E5308097-ADA0-418C-BDCE-16A635FDB17EQ35976932-0392A576-6610-4760-A298-F55E686CE603Q35977382-2FA2D74D-B69C-4A66-8039-8E0D60BD9C85Q35978446-4E62C29C-A4F4-465A-A53F-25C22E1793EBQ35993433-F80B2988-6C67-4BD8-B162-A702AC73D3FEQ35994246-69B6B02B-77D0-487A-BA45-165ED7287837Q35994568-86D9FCD5-9E9C-4CBA-884A-D749F1FFFC45Q36080770-0268022B-331A-408B-BE68-CE154FF7881BQ36292342-BF842B4C-FAF5-4AEB-8303-8AEF52BF41ECQ36466230-AFE2858C-0C34-4C35-8618-0706B1DFA9A5Q36466963-D8A268BE-D7BE-43BC-AA86-F4F515803AB8Q36495579-452489BC-ACE1-4890-90F9-4D33D0B338C0Q36812960-10ADA5D4-D15F-42D1-9C31-CB2BD9521A41Q37239081-9E258688-8BD5-48DE-B5D4-CAFC3A9F1F4AQ37327791-E43B74AD-30F0-4FC9-8A52-41BBB6610EE1Q37607274-C3A94359-AEAE-40C8-B119-771458EE9DE1Q37663392-988F1433-7C2C-405B-9623-8F1637EA494BQ37932556-9B52DAA2-6642-475E-AB15-9808FDD2A0EBQ38001734-E0197A3D-632E-43EB-AB93-C7119AA1999CQ38055067-0E3052A7-5FF3-4116-9214-D5B0FC5E0060Q38410843-4840D3FE-09BC-4619-B173-6AFE910BAB4CQ38758230-DF4F7840-2061-4267-ACA5-1C0B026934ACQ39196784-1A132034-C601-4DA9-A7FC-5ED954796AA7
P2860
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
@en
type
label
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
@en
prefLabel
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
@en
P2093
P356
P1476
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
@en
P2093
J E Parrillo
R E Cunnion
R W Klecker
T C Hamilton
Y Ostchega
P304
P356
10.1200/JCO.1987.5.4.641
P407
P577
1987-04-01T00:00:00Z